Abstract
An investigation of human splenic LAK cells killing autologous tumor invivo has been performed in this study. Briefly, an ovary embryo carcinoma (OEC) removed surgically from patient was transplanted into nude mice (s. c.) and culturedin vitro, that would be used as targets. Lymphokine-activated killer (LAK) cells were generated from splenic lymphocytes of the OEC patient, who died two and half months after operation, by co- culture with recombinant human interleukin- 2 (rIL- 2) invitro. The results from Winn’ s test in nude mice suggested that these LAK cells could effectively inhibit the tumorigenicity of autologous tumorin vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grimm E A, et al. Lymphokine-activated killer cells phenomenon. J Exp Med 1982; 155: 1823.
Mule J J, et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and rIL-2. J Immunol Metho. 1988; 114:3.
Rosenberg S A, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose rIL-2. J Exp Med 1985; 161:1169.
Rayner A A, et al. Lymphokine-activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985; 55:1327.
Schwarz R E and Hiserodt J C. The importance of splenectomy for the adoptive immunotherapy of cancer. Med Hypotheses 1989; 28:165.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhang, B., Tang, Y., Zheng, J. et al. Researches on the anti-autologous tumor effects of human cancer-killing cells in nude mice. Chin J Cancer Res 4, 30–32 (1992). https://doi.org/10.1007/BF02996399
Issue Date:
DOI: https://doi.org/10.1007/BF02996399